No Walk in the Park
Buck Stops at the Top With FDA Enforcement
By Mari Serebrov
Monday, May 21, 2012
Being the CEO of a U.S. biopharma company is a whole lot riskier these days as the FDA continues to keep its promise to hold corporate officials accountable for the off-label promotion activities of their companies and employees.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.